Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

3D-MRE and 2D-MRE for Assessing Cirrhosis and Portal Hypertension

NCT06205992 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2022-08-16
Last updated
2026-02-09

Condition(s) studied

CirrhosisLiver Portal Hypertension

Investigational drug(s) / intervention(s)

3D-MREHVPG2D-MREHVPG

3D-MRE: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.

HVPG: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures

2D-MRE: All imaging studies were performed by using a 3.0-T MRI system (Signa HDx, GE Healthcare) with an eight-channel phasedarray body coil.

HVPG: HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures

Study summary

How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis. We plan to compare the ability of three demensional-magnetic resonance elastography (3D-MRE) to two demensional-magnetic resonance elastography (2D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. age \> 18 years old 2. confirmed cirrhosis (laboratory, imaging and clinical symptoms) 3. with 3D-MRE and 2D-MRE within 1 month prior to HVPG measurement 4. written informed consent Exclusion Criteria: 1. any previous liver or spleen surgery 2. liver cancer; chronic acute liver failure 3. acute portal hypertension 4. unreliable HVPG, 3D-MRE or 2D-MRE results due to technical reasons 5. with liver interventional therapy between HVPG and MRE

Primary outcome measure(s)

  • Accuracy of the features of 3D-MRE and 2D-MRE for assessing portal hypertension in cirrhosis. — 12 months
    WIth HVPG as reference standand, the overall diagnostic perforemace (accuracy) for cirrhosis and portal hypertension of 3D-MRE and 2D-MRE was compared.

Trial sites (1)

FacilityCityRegionStatus
Shengjing Hospital of China Medical University Shenyang Liaoning Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06205992 on ClinicalTrials.gov ↗ ← All trials in China